KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02162 KEYMED BIO-B

Market Closed 08-14 16:08:36

78.150

-1.000

-1.26%

High79.700	Low77.050	Vol1.17M
Open79.700	D1 Closing79.150	Amplitude3.35%
Mkt Cap23.37B	Tradable Cap23.37B	Total Shares299.00M
T/O91.24M	T/O Rate0.39%	Tradable Shares299.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":78.15,"timestamp":1786694916004,"preClose":79.15,"halted":0,"volume":1168500,"delay":0,"changeRate":-0.012634238787113075,"floatShares":299000000,"shares":299000000,"eps":-2.2222307058500417,"marketStatus":"Market Closed","change":-1,"latestTime":"08-14 16:08:36","open":79.7,"high":79.7,"low":77.05,"amount":91243779,"amplitude":0.033481,"askPrice":78.15,"askSize":1500,"bidPrice":78.05,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.253644438341116,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":7,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":79.15,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.4854345538530415,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2658443604","title":"Keymed Biosciences (SEHK:2162) Hits A Phase III Milestone, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658443604","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658443604?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:28","pubTimestamp":1786321721,"startTime":"0","endTime":"0","summary":"Keymed Biosciences (SEHK:2162) is back in focus after announcing that CMG901, its CLDN18.2-targeting antibody drug conjugate co developed with AstraZeneca, met primary and key secondary overall survival endpoints in a global Phase III gastric cancer trial.\nSee our latest analysis for Keymed Biosciences.\nThe positive CMG901 news arrives after a strong run in Keymed Biosciences, with the share price at HK$81.85 and a year to date share price return of 53.13%, while the 3 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-hits-a-phase-iii-milestone-is-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-hits-a-phase-iii-milestone-is-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4134","BK1587","BK1574","02162","III","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112893595","title":"Keymed Bio-B (02162) Announces Phase II Trial Success for CM512 in Chronic Sinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=1112893595","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112893595?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:12","pubTimestamp":1786320748,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) has announced that the Phase II clinical study of its independently developed Class 1 new drug, CM512 injection, for the treatment of chronic rhinosinusitis with nasal polyps...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBQ","BK1161","BK1583","IBBJ","MDTX","PSYK","BK1587","ENTL","BK1574","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101870301","title":"Keymed Biosciences: Phase II Trial of Bispecific Antibody CM512 Meets All Endpoints in Chronic Rhinosinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=1101870301","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101870301?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:03","pubTimestamp":1786320228,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (stock code: 02162) announced that its Phase II clinical study of CM512, a first-in-class long-acting TSLP × IL-13 bispecific antibody, met every predefined endpoint in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605603","title":"Keymed Biosciences Says Phase II Trial of CM512 Meets Endpoints in Chronic Rhinosinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605603","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658605603?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:01","pubTimestamp":1786320063,"startTime":"0","endTime":"0","summary":"Keymed Biosciences says Phase II trial of CM512 meets endpoints in chronic rhinosinusitis with nasal polypsKeymed Biosciences reported its Phase II trial of CM512 for chronic rhinosinusitis with nasal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLcclLsG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02162","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182144730","title":"Keymed Biosciences Sets 19 Aug 2026 Board Meeting to Approve 1H26 Interim Results and Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1182144730","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182144730?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:46","pubTimestamp":1786092387,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. will convene its board of directors on 19 August 2026 to review and approve the interim financial statements for the six months ended 30 June 2026. The agenda also includes...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136927321","title":"Movement Alert｜KEYMED BIO-B Rises 5.46% in Regular Trading, Multiple Institutions Cross 5% Threshold Amid Pipeline Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1136927321","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136927321?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:31","pubTimestamp":1786073502,"startTime":"0","endTime":"0","summary":"On August 7, KEYMED BIO-B rose 5.46% in regular trading, trading at HK$81.2/share, with turnover of HK$63.72 million.The rally was driven by concentrated institutional accumulation. Data disclosed on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128812225","title":"Orient Securities Company Limited Boosts Stake in Keymed Biosciences Inc with HK$14.8 Million Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=1128812225","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128812225?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015343,"startTime":"0","endTime":"0","summary":"Hong Kong Stock Exchange filings reveal that on July 30, Orient Securities Company Limited increased its position in KEYMED BIO-B (02162) by acquiring 203,500 shares.The transaction was executed at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03958","BK0028","02162","BK0183","600958","EWH","BK0188","BK1161","BK1564","BK1587","BK0276","BK1583","BK1147","BK0012","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154329145","title":"KEYMED BIO-B: DFZQ Acquires Shares, Long Position Rises to 5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154329145","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154329145?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:12","pubTimestamp":1786007532,"startTime":"0","endTime":"0","summary":"On July 30, 2026, DFZQ bought 203,500 shares of KEYMED BIO-B at an average of HKD 72.8753 per share, involving about HKD 14.83 million.Prior to the acquisition, DFZQ's long position in KEYMED BIO-B...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657794355","title":"The Bull Case For Keymed Biosciences (SEHK:2162) Could Change Following Key Phase III Oncology Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2657794355","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657794355?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:21","pubTimestamp":1785957719,"startTime":"0","endTime":"0","summary":"In late July 2026, Keymed Biosciences announced positive global Phase III results for CMG901 (sonesitatug vedotin, AZD0901) in CLDN18.2-positive advanced gastric and related cancers, alongside Breakthrough Therapy Designation in China for its bispecific antibody CM512 in chronic rhinosinusitis with nasal polyps.\nThese developments highlight Keymed’s progress in both oncology and immunology, anchored by its AstraZeneca partnership and a growing late-stage pipeline of first-in-class or highly...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/the-bull-case-for-keymed-biosciences-sehk2162-could-change-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/the-bull-case-for-keymed-biosciences-sehk2162-could-change-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["III","BK1583","BK1574","BK1161","02162","BK4134","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122995988","title":"Asset Manager Raises Stake in KEYMED BIO-B with HK$14.8 Million Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1122995988","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122995988?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:20","pubTimestamp":1785842422,"startTime":"0","endTime":"0","summary":"Hong Kong Stock Exchange filings reveal that on July 30, China Universal Asset Management Co., Ltd. increased its position in KEYMED BIO-B (02162) by 203,500 shares.The transaction was executed at an...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1574","BK1587","BK1583","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167820107","title":"Movement Alert｜KEYMED BIO-B Falls 5.38% in Regular Trading, CMG901 Phase III Positive Data Triggers Sell-the-News Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1167820107","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167820107?lang=en_us&edition=fundamental","pubTime":"2026-07-29 09:50","pubTimestamp":1785289802,"startTime":"0","endTime":"0","summary":"On July 29, KEYMED BIO-B fell 5.38% in regular trading, trading at 74.0 HKD/share with turnover of approximately 51.91 million HKD, extending the prior session's decline.On the news front, the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"KEYMED BIO-B Falls; CMG901 Phase III Positive Data Triggers Sell-the-News Pressure","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654077579","title":"Hong Kong Stocks Edge Higher Ahead of Central Bank Meetings; Keymed Biosciences Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2654077579","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654077579?lang=en_us&edition=fundamental","pubTime":"2026-07-28 16:53","pubTimestamp":1785228813,"startTime":"0","endTime":"0","summary":"Hong Kong stocks closed higher on Tuesday as investors await key central bank meetings and earnings from major U.S. technology companies.The Hang Seng Index gained 103.67 points, or 0.4%, to close at 25,310.85, while the Hang Seng China Enterprises Index rose 70.87 points, or 0.9%, to 8,436.25.Hong Kong technology shares were a little resilient as compared to regional peers even as renewed concerns over artificial intelligence spending triggered another selloff in global chipmakers and weighed on broader Asian markets.Sentiment also drew support from optimism over China's semiconductor industry after CXMT Corp.'s Shanghai debut and reports of China's progress in domestic immersion DUV lithography technology.Among individual stocks, Keymed Biosciences  fell nearly 6% after reporting that its global phase 3 trial of CMG901, conducted with AstraZeneca, met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["07300","02800","02833","BK1574","07500","03037","BK1161","HSTECH","513600","MHImain","HSI","82800","BK1583","BK1587","02162","07200","MCHmain","83115","09115","03419","HHImain","03115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119100149","title":"Movement Alert｜KEYMED BIO-B Falls 5.59% in Regular Trading, CMG901 Phase 3 Success Triggers Sell-the-News Reaction","url":"https://stock-news.laohu8.com/highlight/detail?id=1119100149","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119100149?lang=en_us&edition=fundamental","pubTime":"2026-07-28 15:49","pubTimestamp":1785224970,"startTime":"0","endTime":"0","summary":"On July 28, KEYMED BIO-B declined 5.59% in regular trading, trading at 77.8 HKD/share, with turnover of HKD 476 million.On the news front, the company announced that CMG901 (AZD0901), a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"KEYMED BIO-B Falls as CMG901 Phase 3 Success Triggers Sell-the-News Reaction","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654076063","title":"Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654076063","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654076063?lang=en_us&edition=fundamental","pubTime":"2026-07-28 14:43","pubTimestamp":1785221026,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  and AstraZeneca's global phase 3 trial of CMG901 met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer, according to a Tuesday filing with the Hong Kong bourse.The trial showed the antibody-drug conjugate significantly improved overall survival compared with investigator's choice of treatment in patients receiving second- or later-line therapy.CMG901 demonstrated a safety profile consistent with previous studies, with no new safety signals identified, the company said.Following the positive Phase 3 results, the company estimates peak annual sales of $3 billion to $5 billion for the drug candidate.Shares of the biopharmaceutical company were down over 5% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1574","BK1161","BK1587","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654207780","title":"Keymed Biosciences Says CLARITY-Gastric01 Phase III Trial Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654207780","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654207780?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:03","pubTimestamp":1785211398,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Biosciences Says CLARITY-Gastric01 Phase III Trial Achieves Positive Topline ResultsJuly 28 -Keymed Biosciences Inc2162.HK:CLARITY-GASTRIC01 PHASE III TRIAL ACHIEVES POSITIVE TOPLINE RESULTSTRIAL MEETS DUAL PRIMARY ENDPOINTS FOR OVERALL SURVIVAL IN ADVANCED GASTRIC CANCERFurther company coverage:2162.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1MJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0920783379.SGD","LU2089984988.USD","LU2468319806.SGD","LU1019632923.USD","LU2293690249.USD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU1481600234.SGD","LU0997586515.USD","03165","BK1587","LU2089284900.SGD","LU1923622614.USD","LU2114397693.USD","IE0002141913.USD","LU0211328371.USD","AZN.UK","LU0784385170.HKD","LU0496365809.HKD","LU1019634622.SGD","LU0553294199.USD","LU0889565080.SGD","LU0266013472.USD","BK5011","LU1267930227.SGD","SG9999001176.USD","LU1003076772.USD","LU0047473722.EUR","02162","LU0077335932.USD","LU0640478417.SGD","LU0792757196.USD","LU1323610961.USD","BK1583","LU1196032939.SGD","LU0661504455.SGD","LU1863844665.USD","LU3187612489.SGD","LU0310800965.SGD","LU2091194634.USD","LU0575583348.USD","LU1061106388.HKD","LU0390134368.USD","LU1267930573.SGD","LU1057294990.SGD","LU0949170426.SGD","LU0310799852.SGD","LU1023059063.AUD","LU2237443382.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654202720","title":"KeyMed Biosciences - Trial Meets Dual Primary Endpoints for Overall Survival in Advanced Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654202720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654202720?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:00","pubTimestamp":1785211241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1MJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1574","BK1583","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654020201","title":"KeyMed Biosciences - Clarity-Gastric01 Phase Iii Trial Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654020201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654020201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:00","pubTimestamp":1785211241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1MJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","02162","BK1587","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653874800","title":"Hong Kong Stocks Rise on Thursday; Tsaker New Energy Soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874800","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653874800?lang=en_us&edition=fundamental","pubTime":"2026-07-23 17:15","pubTimestamp":1784798150,"startTime":"0","endTime":"0","summary":"Hong Kong stocks closed higher on Thursday as investors looked ahead to next week's U.S. Federal Reserve meeting and welcomed a new agreement between Malaysian and Hong Kong regulators to strengthen c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","02800","MCHmain","513600","07500","07300","09115","02833","HHImain","MHImain","BK1587","BK1129","HSTECH","BK1574","03037","BK1161","83115","82800","01986","07200","03115","03419","02162","HSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171394971","title":"Keymed Bio-B Shares Surge Over 3% Following Inclusion of CM512 in China's Breakthrough Therapy Designation List","url":"https://stock-news.laohu8.com/highlight/detail?id=1171394971","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171394971?lang=en_us&edition=fundamental","pubTime":"2026-07-23 14:25","pubTimestamp":1784787923,"startTime":"0","endTime":"0","summary":"Shares of Keymed Bio-B (02162) have risen more than 3%. At the time of writing, the stock is up 2.03%, trading at HK$85.3 with a turnover of HK$85.1319 million.The upward movement follows a company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK4588","02162","KCAI","BK1574","BK1161","BK1583","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184064929","title":"KEYMED BIO-B's CM512 Designated as Breakthrough Therapy for Chronic Rhinosinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=1184064929","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184064929?lang=en_us&edition=fundamental","pubTime":"2026-07-23 12:04","pubTimestamp":1784779464,"startTime":"0","endTime":"0","summary":"An announcement has been made by KEYMED BIO-B (ASX: 02162) regarding its key research and development product, CM512 (TSLP/IL-13 bispecific antibody).The product has been included in the Breakthrough...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1583","02162","BK1587"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.1028},{"period":"3month","weight":0.1832},{"period":"6month","weight":0.4326},{"period":"1year","weight":0.0713},{"period":"ytd","weight":0.4621}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.112367},{"month":8,"riseRate":0.666667,"avgChangeRate":0.043211},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"KEYMED BIO-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KEYMED BIO-B,02162,KEYMED BIO-B股票,KEYMED BIO-B股票老虎,KEYMED BIO-B股票老虎国际,KEYMED BIO-B行情,KEYMED BIO-B股票行情,KEYMED BIO-B股价,KEYMED BIO-B股市,KEYMED BIO-B股票价格,KEYMED BIO-B股票交易,KEYMED BIO-B股票购买,KEYMED BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}